Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994

Lebitasy, Marie-Paule; Hédelin, Guy; Purohit, Ashok; Moreau, L.; Klinzig, F; Quoix, Élisabeth

doi:10.1054/bjoc.2001.1955

Cited by 39 publications

(28 citation statements)

References 46 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the initial response to chemotherapy, most tumors ultimately would develop drug resistance which is associated with the unsatisfied prognosis. Only 10-15% of patients with limited disease (LD) are still alive 2 years after diagnosis, while the overall survival (OS) of patients with extensive disease (ED) is even shorter (2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

Nomogram prediction for the survival of the patients with small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Background: Small cell lung cancer (SCLC) is a subtype of lung cancer with poor prognosis. In this study, we aimed to build a nomogram to predict the survival of individual with SCLC by incorporating significant clinical parameters. Methods:The patients with SCLC were enrolled from the First Affiliated Hospital of Guangzhou Medical University (GMUFAH) between 2009 and 2013. We identified and incorporated the independent prognostic factors to build a nomogram to predict the survival of SCLC patients. The predictive accuracy and discriminative ability of the nomogram were evaluated by concordance index (C-index) and calibration curve.We also compared the accuracy of the built model with the 7 th AJCC TNM and VALSG staging system. The nomogram was further validated in an independent cohort of 80 patients with SCLC from Cancer Center of Guangzhou Medical University (GMUCC) between 2009 and 2013.Results: A total of 275 patients with SCLC were included in the primary cohort, and seven independent prognostic factors were identified including age, N stage, metastasis status, histology, platelets to lymphocyte ratio (PLR), neuron specific enolase (NSE) and CYFRA21-1 as independent prognostic factors after using Cox regression model. A nomogram incorporating these prognostic factors was subsequently built. The calibration curves for possibilities of 1-, 2-year overall survival (OS) revealed optimal agreement between nomogram prediction and actual observation. The C-index of this nomogram was higher than that of TNM Conclusions:In this study, we established and validated a novel nomogram for the prediction of OS for the patients with SCLC. This model could provide more accurate individual prediction of survival probability of SCLC than the existing staging systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Nomogram prediction for the survival of the patients with small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…SCLC is the most aggressive form of pulmonary cancer and, without treatment, the median survival ranges from 2 to 4 months [1,2,3,4]. Unlike other cell types of lung cancer, SCLC is both chemosensitive and radiosensitive; however, most patients have a dismal prognosis.…”

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Small Cell Lung Carcinoma in Taiwan

Kuo¹,

Lin²,

Yang³

et al. 2012

Oncology

View full text Add to dashboard Cite

Background: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. The prognosis for SCLC patients remains unsatisfactory despite advances in chemotherapy. In this study, we sought to clarify the prognosis and treatment patterns of patients with SCLC. Methods: A cohort comprising all patients diagnosed with SCLC between January 2004 and December 2006 was assembled from the Taiwan Cancer Database. Patients were followed up until December 31, 2009, to determine overall survival. Patient survival was estimated using the Kaplan-Meier method, and Cox’s proportional hazard model was used to determine the relationship between prognostic factors and median survival time. Results: Among the 1,684 patients diagnosed with SCLC, 1,215 (72%) were diagnosed with extensive-stage disease and 469 (28%) with limited-stage disease. Most of the patients were male (90%). The median survival duration of patients with limited-stage and extensive-stage SCLC was 10.3 months and 5.6 months, respectively. For limited-stage patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy resulted in better survival than best supportive care (HR 0.20, p < 0.001; HR 0.61, p < 0.001, and HR 0.37, p < 0.001, respectively). For extensive-stage patients, male gender was significantly associated with a poor prognosis (HR 1.45, p < 0.001) and chemotherapy was shown to improve overall survival more effectively than best supportive care (HR 0.37, p < 0.001). Conclusion: For limited-stage SCLC patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy improved survival compared to best supportive care. Extensive-stage SCLC patients benefited more from chemotherapy treatment than from best supportive care.

show abstract

“…In contrast to elderly patients with NSCLC, the majority of elderly patients with SCLC will receive active treatment (chemotherapy and radiotherapy) -only 39/361 of our patients did not receive treatment (Brown et al, 1996). Pooled data of the Southwest Oncology Group (Albain et al, 1990) and CALGB (Spiegelman et al, 1989) showed that age was a significant predictor favouring the younger patient for both limited and extensive disease SCLC although a large French retrospective review of SCLC patients using numerous regimens found no such correlation (Lebitasy et al, 2001). Our median survivals for all these elderly patients are still in the range of reported studies.…”

Section: Discussionmentioning

confidence: 69%

Time and chemotherapy treatment trends in the treatment of elderly patients (age ⩾70 years) with small cell lung cancer

et al. 2005

View full text Add to dashboard Cite

Platinum-based treatment for small cell lung cancer (SCLC) has been established since 1995. This study investigates treatment outcome of elderly patients (age X70 years) with SCLC over the past 20 years in a large UK cancer centre. Comparison of all-cause survival was assessed in patients presenting between two predefined time periods : 1982 -1994 and 1995 -2003. All the survival analysis were adjusted for stage and performance status and age if appropriate. Survival between different chemotherapy treatment regimens was compared. A total of 322 elderly patients (31% of all) registered between 1982 -2003 received chemotherapy for SCLC. Patients presenting in 1995 -2003 had an overall better median survival (43 vs 25 weeks) and a 1-year survival (37 vs 14%) than patients presenting in 1982 -1994. This applied to patients with both limited and extensive stage disease and all age groups. There was a trend towards the use of more platinum-based treatments in the later cohort but the use of radiotherapy remained constant. Patients who received platinum combinations (Carboplatin or Cisplatin) had significantly improved survival over those who received single agents or other combinations (Po0.001) and there was no significant difference between carboplatin and cisplatin (P ¼ 0.7). The analysis demonstrates that there has been a significant improvement in survival for elderly patients with lung cancer treated by chemotherapy in the past 20 years despite more very elderly patients being treated with a poorer performance status. This change is probably multifactorial and may be due to the increased use of platinum-based treatment and improved supportive care.

show abstract

Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994

Cited by 39 publications

References 46 publications

Nomogram prediction for the survival of the patients with small cell lung cancer

Nomogram prediction for the survival of the patients with small cell lung cancer

Survival of Patients with Small Cell Lung Carcinoma in Taiwan

Time and chemotherapy treatment trends in the treatment of elderly patients (age ⩾70 years) with small cell lung cancer

Contact Info

Product

Resources

About